Literature DB >> 22206959

Local extension at the hilum region is associated with worse long-term survival in stage I non-small cell lung cancers.

Chang Chen1, Fang Bao, Hui Zheng, Yi-ming Zhou, Min-wei Bao, Hui-kang Xie, Ge-ning Jiang, Jia-an Ding, Wen Gao.   

Abstract

BACKGROUND: The prognostic significance of hilar structures invasion, which remains undefined for non-small cell lung cancer (NSCLC), may have potential application for cancer staging. Tumor extension along the bronchus and pulmonary vessels was examined for survival significance.
METHODS: In all, 213 pathologically proved central-type stage I NSCLC cases were enrolled. Four study groups were assigned based on the extent of resections: standard lobectomy (group L, n=32), bronchoplastic procedures (group B, n=94), standard lobectomy combined with pulmonary angioplasty (group A, n=48), and bronchial sleeve resection combined with pulmonary artery angioplasty (group BA, n=39). Univariate and multivariate analysis were performed by the Kaplan-Meier method and the Cox regression model.
RESULTS: There were 2 postoperative deaths (pulmonary embolism and serious pulmonary infection). Complications were noted in 39 patients (18.3%). Among these patients, the overall 5-year survival rate was 60.2%±0.05%, with a median survival time of 75.0±7.5 months. The 5-year survival rates of subgroups were 79.5%, 59.7%, 59.0%, and 47.9%, respectively for groups L, B, A, and BA. Univariate analysis indicated tumor size, bronchial invasion, arterial involvement, and type of operation as closely associated with long-term survival. Multivariate analysis indicated that type of operation and tumor size were the most prominent prognostic factors of 5-year survival.
CONCLUSIONS: Proximal tumor extension into bronchus, invasions into extrapericardial pulmonary vessels, and tumor size were the most important risk factors for 5-year survival with central-type stage I NSCLC. Tumor extension in the hilum was highly related to prognosis and might provide pertinent information to accurately define a tumor ("T") subclass.
Copyright © 2012 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22206959     DOI: 10.1016/j.athoracsur.2011.09.079

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  8 in total

1.  Pros: should a medically inoperable patient with a T2N0M0 non-small cell lung cancer central in the lung hilus be treated using stereotactic body radiotherapy?

Authors:  Katrina Woodford; Sashendra Senthi
Journal:  Transl Lung Cancer Res       Date:  2015-10

2.  LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective.

Authors:  S Adebahr; S Collette; E Shash; M Lambrecht; C Le Pechoux; C Faivre-Finn; D De Ruysscher; H Peulen; J Belderbos; R Dziadziuszko; C Fink; M Guckenberger; C Hurkmans; U Nestle
Journal:  Br J Radiol       Date:  2015-04-15       Impact factor: 3.039

Review 3.  Stereotactic radiotherapy for early lung cancer: Evidence-based approach and future directions.

Authors:  Samer Chehade; David A Palma
Journal:  Rep Pract Oncol Radiother       Date:  2014-12-12

4.  Elevation of Neutrophil-to-Lymphocyte Ratio Is a Significant Poor Prognostic Factor in Completely Resected Centrally Located Lung Squamous Cell Carcinoma.

Authors:  Takuma Tsukioka; Nobuhiro Izumi; Hiroaki Komatsu; Hidetoshi Inoue; Ryuichi Ito; Satoshi Suzuki; Noritoshi Nishiyama
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

5.  Size, edge, and stage of NSCLC determine the release of CYFRA 21-1 in bloodstream.

Authors:  Helga Sertić Milić; Ana Franjević; Gordana Bubanović; Ante Marušić; Igor Nikolić; Igor Puljić
Journal:  Wien Klin Wochenschr       Date:  2015-04-28       Impact factor: 1.704

6.  Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy.

Authors:  Ankit Modh; Andreas Rimner; Eric Williams; Amanda Foster; Mihir Shah; Weiji Shi; Zhigang Zhang; Daphna Y Gelblum; Kenneth E Rosenzweig; Ellen D Yorke; Andrew Jackson; Abraham J Wu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-10-08       Impact factor: 7.038

7.  Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma.

Authors:  Yunqiang Nie; Wei Gao; Na Li; Wenjun Chen; Hui Wang; Cuiyun Li; Haiyan Zhang; Ping Han; Yingmei Zhang; Xin Lv; Xinyi Xu; Hongyan Liu
Journal:  World J Surg Oncol       Date:  2017-03-03       Impact factor: 2.754

8.  Low-dose hilar and mediastinal stereotactic body radiation therapy for non-small cell lung cancer: Analysis of outcomes in patients receiving one or multiple courses of treatment.

Authors:  Roman O Kowalchuk; Michael R Waters; Martin Richardson; Kelly Spencer; James M Larner; Charles R Kersh
Journal:  Thorac Cancer       Date:  2020-05-29       Impact factor: 3.500

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.